Of these, only one persistent residual adenoma was seen on further surveillance. Of 25 patients where ≥2 or more follow-up endoscopies were available, only one persistent ICG-001 datasheet recurrence was found. Overall, endoscopic and histological residual/recurrence occurred in 14.5% and 10.0%, respectively. This was successfully treated in 90%. Conclusions: In a tertiary referral centre, EMR of SDAs is a safe and effective alternative to surgery. Pre-EMR biopsies appear not to contribute to the patient’s management. Intra-procedural bleeding does not predict further complications. Delayed bleeding is associated with

lesion size and number of resected specimens. A structured surveillance program is essential, recurrence is uncommon and can be easily treated endoscopically. M-Y(A) CHUANG,1,3 PY ONG,3 SB FANNING2 1Department of Medicine,

Flinders Medical Centre, SA, Australia, 2Department of Gastroenterology, Launceston General Hospital, TAS, Australia, 3School of Medicine, University of Tasmania, TAS, Australia Introduction: Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has become widely accepted as an effective, minimally invasive diagnostic tool for the evaluation of solid and cystic lesions of the gastrointestinal (GI) and check details respiratory tract. Although an increasing number of major tertiary centers have adopted EUS-FNA as a standard diagnostic tool, the availability of EUS-FNA in regional areas is still limited. To our knowledge,

there are currently no reports on its performance in this setting in the literature. EUS was first introduced in our regional 300-bed hospital servicing Northern Tasmania in 2013. Here we report our single-operator experience with EUS-FNA with regard to clinical utility, diagnostic accuracy, and safety. Methods: Data was prospectively collected on consecutive EUS procedures performed at the Launceston General Hospital between January 2013 and April 2014. Patient demographics and the operating characteristics MCE公司 of EUS-FNA were recorded. Final diagnosis was based on a composite standard: histologic evidence at surgery, or non-equivocal cytology on FNA and follow-up. Results: A total of 144 EUS examinations with 86 EUS-FNA were performed during the study period (50 men, mean age 68 years, range 39–89). These included 37 solid pancreatic lesions, 11 cystic pancreatic lesions, 21 lymph nodes, 10 subepithelial GI lesions, and 7 intra-abdominal or mediastinal lesions (see Table 1). 25-gauge needle was used in 72 cases, and 22-gauge needle in 12 cases. Mean solid lesion size was 30 mm (range 5–62 mm) with a median of 2 needle passes per lesion (range 1–6) to obtain a diagnosis. Adequate material, as assessed by in-room cytopathologist, was obtained from all solid pancreatic lesions, lymph nodes, and 9 of 10 subepithelial GI lesions. Malignant pathology was diagnosed in 73.0, 76.2, and 80.0% of cases respectively.